Marinus Pharmaceuticals Inc (MRNS) - Price-to-Projected Revenue Ratio

Corporate company logo of Marinus Pharma (MRNS)

The forward P/S trend on this GURU.Markets chart has stabilized at 1.00, correlating with the commercial promotion of Ztalmy and expansion into global markets. Marinus Pharmaceuticals is currently optimizing expenses and narrowing its R&D pipeline to secure approval for oral ganaxolone. Revenues for Marinus Pharmaceuticals are based on the sale of genetic epilepsy medications and the development of hospital-grade pharmaceuticals.

marinuspharma.com - MRNS Forward Price to Sales (period 07/04/2022 - 02/22/2025)

Comprehensive metric breakdowns and analytics for marinuspharma.com (MRNS)

- stock price and consensus target price:
Analysis of all company metrics:Marinus Pharmaceuticals Inc MRNS
Original product of Marinus Pharmaceuticals

The forward P/S ratio compares the market value of Marinus Pharmaceuticals (MRNS) to projected revenue, allowing for an assessment of the premium paid for future growth and the determination of the investment's margin of safety. By analyzing the forward P/S history, an investor can see how patent protection for steroid drugs and the orphan drug status of seizure medications support a high business valuation while minimizing the risks of generic expansion.

Competitors of Marinus Pharmaceuticals

Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cyclerion.com CYCN|Forward P/S Multiple PTIX|KTTA - Market Cap to Future Revenue Ratio|Forward P/S Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics Inc (ATXI) - Market Cap to Future Revenue Ratio|BCLI - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio caratherapeutics.com|CHRO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Eliem Therapeutics (ELYM)|ITCI (Intra-Cellular Therapies Inc.) - Forward P/S Multiple|Forward P/S Multiple Longboard|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple